
Inizio helped Tonix successfully launch the first FDA-approved therapy in its class in almost two decades by delivering an integrated, AI-enabled commercialization program spanning analytics, field operations, and launch readiness.

AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing...

Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.

The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments....

Inizio has appointed Oisín Ó Gógáin as Chief People Officer.

In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.

This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.

Genesis Research Group today announced the appointment of Sarah Alwardt, PhD, as Executive Vice President, RWE/HEOR. She joins the Executive Leadership Team and will lead the company’s global real-world evidence...

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize...